Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-8d8f8c8dd8b6d0af13b2bc71d6fa0c36"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-8d8f8c8dd8b6d0af13b2bc71d6fa0c36"/>
<resource>
<Composition>
<id value="composition-en-8d8f8c8dd8b6d0af13b2bc71d6fa0c36"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-8d8f8c8dd8b6d0af13b2bc71d6fa0c36"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-8d8f8c8dd8b6d0af13b2bc71d6fa0c36</b></p><a name="composition-en-8d8f8c8dd8b6d0af13b2bc71d6fa0c36"> </a><a name="hccomposition-en-8d8f8c8dd8b6d0af13b2bc71d6fa0c36"> </a><a name="composition-en-8d8f8c8dd8b6d0af13b2bc71d6fa0c36-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/12/777/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - inlyta</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/12/777/001"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mp8d8f8c8dd8b6d0af13b2bc71d6fa0c36"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - inlyta"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet</p><ol type="1"><li>What Inlyta is and what it is used for</li><li>What you need to know before you take Inlyta</li><li>How to take Inlyta</li><li>Possible side effects</li><li>How to store Inlyta</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What inlyta is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What inlyta is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Inlyta is a medicine containing the active substance axitinib. Axitinib reduces the blood supply to the tumour and slows down the growth of cancer.</p><p>Inlyta is indicated for the treatment of advanced kidney cancer (advanced renal cell carcinoma) in adults, when another medicine (called sunitinib or a cytokine) is no longer stopping disease from progressing.</p><p>If you have any questions about how this medicine works or why this medicine has been prescribed for you, ask your doctor.</p></div>
</text>
</section>
<section>
<title value="2. What you need to know before you take inlyta"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="2. What you need to know before you take inlyta"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Do not take Inlyta: If you are allergic to axitinib or any of the other ingredients of this medicine (listed in section 6). If you think you may be allergic, ask your doctor for advice.</p><p>Warnings and precautions</p><p>Talk to your doctor or nurse before taking Inlyta</p><ul><li><p>If you have high blood pressure. Inlyta can raise your blood pressure. It is important to check your blood pressure before you take this medicine, and regularly while you are taking it. If you have high blood pressure (hypertension) you may be treated with medicines to reduce the blood pressure. Your doctor should make sure that your blood pressure is under control before starting Inlyta treatment, and while on treatment with this medicine.</p></li><li><p>If you have thyroid gland problems. Inlyta can cause thyroid gland problems. Tell your doctor if you get tired more easily, generally feel colder than other people, or your voice deepens whilst taking this medicine. Your thyroid function should be checked before you take Inlyta and regularly while you are taking it. If your thyroid gland is not producing enough thyroid hormone before, or while on treatment with this medicine, you should be treated with thyroid hormone replacement.</p></li><li><p>If you have had a recent problem with blood clots in your veins and arteries (types of blood vessels), including stroke, heart attack, embolism, or thrombosis.<br/>Get emergency help right away and call your doctor if you get symptoms such as chest pain or pressure; pain in your arms, back, neck or jaw; shortness of breath; numbness or weakness on one side of your body; trouble talking; headache; vision changes; or dizziness while on treatment with this medicine.</p></li><li><p>If you suffer from bleeding problems. Inlyta may increase your chance of bleeding. Tell your doctor if you have any bleeding, coughing up of blood or bloody sputum while on treatment with this medicine.</p></li><li><p>If you have or have had an aneurysm (enlargement and weakening of a blood vessel wall) or a tear in a blood vessel wall.</p></li><li><p>If during treatment with this medicine you get severe stomach (abdominal) pain or stomach pain that does not go away. Inlyta may increase the risk of developing a hole in the stomach or intestine or formation of fistula (abnormal tube-like passage from one normal body cavity to another body cavity or the skin). Tell your doctor if you have severe abdominal pain while on treatment with this medicine.</p></li><li><p>If you are going to have an operation or if you have an unhealed wound. Your doctor should stop Inlyta at least 24 hours before your operation as it may affect wound healing. Your treatment with this medicine should be restarted when the wound has adequately healed.</p></li><li><p>If during treatment with this medicine, you get symptoms such as headache, confusion, seizures (fits), or changes in vision with or without high blood pressure. Get emergency help right away and call your doctor. This could be a rare neurological side effect named posterior reversible encephalopathy syndrome.</p></li><li><p>If you have liver problems. Your doctor should do blood tests to check your liver function before and during treatment with Inlyta.</p></li><li><p>If during treatment with this medicine, you get symptoms such as excessive tiredness, swelling of the abdomen, legs or ankles, shortness of breath, or protruding neck veins. Inlyta may increase the risk of developing heart failure events. Your doctor should monitor for signs or symptoms of heart failure events periodically throughout treatment with axitinib.</p></li></ul><p>Use in children and adolescents Inlyta is not recommended for people aged under 18. This medicine has not been studied in children and adolescents.</p><p>Other medicines and Inlyta Some medicines may affect Inlyta, or be affected by it. Please tell your doctor, pharmacist or nurse about all the medicines you have recently taken, are currently taking, or plan to take, including medicines obtained without a prescription, vitamins, and herbal medicines. The medicines listed in this leaflet may not be the only ones that could interact with Inlyta.</p><p>The following medicines may increase the risk of side effects with Inlyta:</p><ul><li>ketoconazole or itraconazole, used to treat fungal infections;</li><li>clarithromycin, erythromycin or telithromycin, antibiotics used to treat bacterial infections;</li><li>atazanavir, indinavir, nelfinavir, ritonavir or saquinavir, used to treat HIV infections/AIDS;</li><li>nefazodone, used to treat depression.</li></ul><p>The following medicines may reduce the effectiveness of Inlyta:</p><ul><li>rifampicin, rifabutin or rifapentin, used to treat tuberculosis (TB);</li><li>dexamethasone, a steroid medicine prescribed for many different conditions, including serious illnesses;</li><li>phenytoin, carbamazepine or phenobarbital, anti-epileptics used to stop seizures or fits;</li><li>St. John s wort (Hypericum perforatum), a herbal product used to treat depression.</li></ul><p>You should not take these medicines during your treatment with Inlyta. If you are taking any of them, tell your doctor, pharmacist or nurse. Your doctor may change the dose of these medicines, change the dose of Inlyta, or switch you to a different medicine.</p><p>Inlyta may increase side effects associated with theophylline, used to treat asthma or other lung diseases.</p><p>Inlyta with food and drink</p><p>Do not take this medicine with grapefruit or grapefruit juice, as it may increase the chance of side effects.</p><p>Pregnancy and breast-feeding</p><ul><li><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor, pharmacist or nurse for advice before taking this medicine.</p></li><li><p>Inlyta could harm an unborn baby or breast-fed baby.</p></li><li><p>Do not take this medicine during pregnancy. Talk to your doctor before taking it if you are pregnant or might become pregnant.</p></li><li><p>Use a reliable method of contraception while you are taking Inlyta and up to 1 week after the last dose of this medicine, to prevent pregnancy.</p></li><li><p>Do not breast-feed during treatment with Inlyta. If you are breast-feeding, your doctor should discuss with you whether to discontinue breast-feeding or discontinue Inlyta treatment.</p></li></ul><p>Driving and using machines</p><p>If you experience dizziness and/or feel tired while on treatment with Inlyta, take special care when driving or using machines.</p><p>Inlyta contains lactose</p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p><p>Inlyta contains sodium</p><p>This medicine contains less than 1 mmol (23 mg) sodium per film-coated tablet, that is to say essentially sodium-free .</p></div>
</text>
</section>
<section>
<title value="3. How to take inlyta"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take inlyta"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Always take this medicine exactly as your doctor has told you. You should check with your doctor, pharmacist or nurse if you are not sure.</p><p>The recommended dose is 5 mg twice a day. Your doctor may subsequently increase or decrease your dose depending on how you tolerate treatment with Inlyta.</p><p>Swallow the tablets whole with water, with or without food. Take the Inlyta doses approximately 12 hours apart.</p><p>If you take more Inlyta than you should If you accidentally take too many tablets or a higher dose than you need, contact a doctor for advice right away. If possible, show the doctor the pack, or this leaflet. You may require medical attention.</p><p>If you forget to take Inlyta Take your next dose at your regular time. Do not take a double dose to make up for the forgotten tablets.</p><p>If you vomit while taking Inlyta If you vomit, an additional dose should not be taken. The next prescribed dose should be taken at the usual time.</p><p>If you stop taking Inlyta If you are not able to take this medicine as your doctor prescribed or you feel you do not need it anymore, contact your doctor right away.</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Some side effects could be serious. You must immediately contact your doctor if you experience any of those following serious side effects (see also section 2 What you need to know before you take Inlyta ):</p><ul><li><p>Heart failure events. Tell your doctor if you experience excessive tiredness, swelling of the abdomen, legs, or ankles, shortness of breath, or protruding neck veins.</p></li><li><p>Blood clots in your veins and arteries (types of blood vessels), including stroke, heart attack, embolism, or thrombosis. Get emergency help right away and call your doctor if you get symptoms such as chest pain or pressure; pain in your arms, back, neck or jaw; shortness of breath; numbness or weakness on one side of your body; trouble talking; headache; vision changes: or dizziness.</p></li><li><p>Bleeding. Tell your doctor right away if you have any of these symptoms or a serious bleeding problem during treatment with Inlyta: black tarry stools, coughing up of blood or bloody sputum, or change in your mental status.</p></li><li><p>Hole in the stomach or intestine or formation of fistula (abnormal tube-like passage from one normal body cavity to another body cavity or the skin). Tell your doctor if you have severe abdominal pain.</p></li><li><p>Severe increase in blood pressure (hypertensive crisis). Tell your doctor if you have a very high blood pressure, severe headache, or severe chest pain.</p></li><li><p>Reversible swelling of the brain (posterior reversible encephalopathy syndrome). Get emergency help right away and call your doctor if you get symptoms such as headache, confusion, seizures (fits), or changes in vision with or without high blood pressure.</p></li></ul><p>Other side effects with Inlyta may include:</p><p>Very common: may affect more than 1 in 10 people</p><ul><li>High blood pressure, or increases in blood pressure</li><li>Diarrhoea, feeling or being sick (nausea or vomiting), stomach ache, indigestion, soreness of the mouth, tongue or throat, constipation</li><li>Shortness of breath, cough, hoarseness</li><li>Lack of energy, feeling weak or tired</li><li>Under-active thyroid gland (may show in your blood tests)</li><li>Redness and swelling of the palms of the hands or soles of the feet (hand-foot syndrome), skin rash, dryness of the skin</li><li>Joint pain, pain in hands or feet</li><li>Loss of appetite</li><li>Protein in the urine (may show in your urine tests)</li><li>Weight loss</li><li>Headache, taste disturbance or loss of taste</li></ul><p>Common: may affect up to 1 in 10 people</p><ul><li>Dehydration (loss of body fluids)</li><li>Kidney failure</li><li>Flatulence (wind), haemorrhoids, bleeding from gums, bleeding from the rectum, a burning or stinging sensation in the mouth</li><li>Hyper-active thyroid gland (may show in your blood tests)</li><li>Sore throat or nose and throat irritation</li><li>Muscle pain</li><li>Nose bleeding</li><li>Skin itching, redness of the skin, hair loss</li><li>Ringing/sound in the ears (tinnitus)</li><li>Reduction in the number of red blood cells (may show in your blood tests)</li><li>Reduction in the number of blood platelets (cells that help blood to clot) (may show in your blood tests)</li><li>Presence of red blood cells in the urine (may show in your urine tests)</li><li>Changes in the levels of different chemicals/enzymes in the blood (may show in your blood tests)</li><li>Increase in the number of red blood cells (may show in your blood tests)</li><li>Swelling of the abdomen, legs, or ankles, protruding neck veins, excessive tiredness, shortness of breath (signs of heart failure events)</li><li>Fistula (abnormal tube like passage from one normal body cavity to another body cavity or the skin)</li><li>Dizziness</li><li>Inflammation of the gall bladder</li></ul><p>Uncommon: may affect up to 1 in 100 people</p><ul><li>Reduction in the number of white blood cells (may show in your blood tests)</li></ul><p>Not known: frequency cannot be estimated from the available data</p><ul><li>An enlargement and weakening of a blood vessel wall or a tear in a blood vessel wall (aneurysms and artery dissections). Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</li></ul></div>
</text>
</section>
<section>
<title value="5. How to store inlyta"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store inlyta"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton and on the blister foil or bottle after EXP . The expiry date refers to the last day of the month.</p><p>This medicine does not require any special storage conditions.</p><p>Do not use any pack that is damaged or shows signs of tampering.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What Inlyta contains</p><ul><li><p>The active substance is axitinib. Inlyta film-coated tablets come in different strengths. Inlyta 1 mg: each tablet contains 1 mg axitinib Inlyta 3 mg: each tablet contains 3 mg axitinib Inlyta 5 mg: each tablet contains 5 mg axitinib Inlyta 7 mg: each tablet contains 7 mg axitinib</p></li><li><p>The other ingredients are microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, magnesium stearate, hypromellose 2910 (15 mPa s), titanium dioxide (E171), triacetin (E1518), iron oxide red (E172) (see section 2 Inlyta contains lactose).</p></li></ul><p>What Inlyta looks like and contents of the pack</p><p>Inlyta 1 mg film-coated tablets are red, oval and debossed with Pfizer on one side and 1 XNB on the other. Inlyta 1 mg is available in bottles of 180 tablets and blisters of 14 tablets. Each blister pack contains 28 tablets or 56 tablets.</p><p>Inlyta 3 mg film-coated tablets are red, round and debossed with Pfizer on one side and 3 XNB on the other. Inlyta 3 mg is available in bottles of 60 tablets and blisters of 14 tablets. Each blister pack contains 28 tablets or 56 tablets.</p><p>Inlyta 5 mg film-coated tablets are red, triangular and debossed with Pfizer on one side and 5 XNB on the other. Inlyta 5 mg is available in bottles of 60 tablets and blisters of 14 tablets. Each blister pack contains 28 tablets or 56 tablets.</p><p>Inlyta 7 mg film-coated tablets are red, diamond shaped and debossed with Pfizer on one side and 7 XNB on the other. Inlyta 7 mg is available in bottles of 60 tablets and blisters of 14 tablets. Each blister pack contains 28 tablets or 56 tablets.</p><p>Not all pack sizes may be marketed.</p><p>Marketing Authorisation Holder</p><p>Pfizer Europe MA EEIG Boulevard de la Plaine 1050 Bruxelles Belgium</p><p>Manufacturer</p><p>Pfizer Manufacturing Deutschland GmbH Betriebsst tte Freiburg Mooswaldallee 1 79090 Freiburg Germany</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:</p><p>Belgique/ Belgi /Belgien Pfizer SA/NV T l/Tel: +32 (0)2 554 62 Lietuva Pfizer Luxembourg SARL filialas Lietuvoje Tel. + 370 52 51 4<br/>,<br/>.: +359 2 970 4Luxembourg/Luxemburg Pfizer S.A. T l/Tel: +32 (0)2 554 62 esk republika Pfizer, spol. s r.o. Tel: +420 283 004 Magyarorsz g Pfizer Kft. Tel.: +36-1-488-37-Danmark Pfizer ApS Tlf: +45 44 20 11 Malta Vivian Corporation Ltd. Tel: +356 21344Deutschland PFIZER PHARMA GmbH Tel: +49 (0)30 550055 51Nederland Pfizer BV Tel: +31 (0)10 406 43 Eesti Pfizer Luxembourg SARL Eesti filiaal<br/>Tel.: +372 666 7Norge Pfizer AS Tlf: +47 67 52 61<br/>Pfizer A.E. : +30 210 6785 sterreich Pfizer Corporation Austria Ges.m.b.H. Tel: +43 (0)1 521 15-0</p><p>Espa a Pfizer S.L. T l: +34 91 490 99 Polska Pfizer Polska Sp. z o.o. Tel.:+48 22 335 61 France Pfizer<br/>T l: +33 (0)1 58 07 34 Portugal Laborat rios Pfizer, Lda. Tel: +351 21 423 5Hrvatska<br/>Pfizer Croatia d.o.o. Tel: + 385 1 3908 Rom nia Pfizer Romania S.R.L. Tel: +40 (0) 21 207 28 Ireland Pfizer Healthcare Ireland Tel: 1800 633 363 (toll free) +44 (0)1304 616Slovenija Pfizer Luxembourg SARL Pfizer, podru nica za svetovanje s podro ja farmacevtske dejavnosti, Ljubljana Tel.: + 386 (0)1 52 11 sland Icepharma hf. S mi: +354 540 8Slovensk republika Pfizer Luxembourg SARL, organiza n zlo ka<br/>Tel.: + 421 2 3355 5Italia Pfizer S.r.l. Tel: +39 06 33 18 Suomi/Finland Pfizer Oy Puh./Tel: +358 (0)9 43 00 K<br/>Pfizer . . (Cyprus Branch)<br/>: +357 22 817Sverige<br/>Pfizer AB Tel: +46 (0)8 550 520 Latvija Pfizer Luxembourg SARL fili le Latvij<br/>Tel.: + 371 670 35 United Kingdom (Northern Ireland) Pfizer Limited Tel: +44 (0) 1304 616This leaflet was last revised in</p><p>Other sources of information</p><p>Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mp8d8f8c8dd8b6d0af13b2bc71d6fa0c36"/>
<resource>
<MedicinalProductDefinition>
<id value="mp8d8f8c8dd8b6d0af13b2bc71d6fa0c36"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mp8d8f8c8dd8b6d0af13b2bc71d6fa0c36"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mp8d8f8c8dd8b6d0af13b2bc71d6fa0c36</b></p><a name="mp8d8f8c8dd8b6d0af13b2bc71d6fa0c36"> </a><a name="hcmp8d8f8c8dd8b6d0af13b2bc71d6fa0c36"> </a><a name="mp8d8f8c8dd8b6d0af13b2bc71d6fa0c36-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/12/777/001</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Inlyta 1 mg film-coated tablets</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/12/777/001"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName value="Inlyta 1 mg film-coated tablets"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
